Approval · Notice of Compliance 30157 · 2023
AZOPT: Notice of Compliance 30157
Issued February 10, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30157
- Date
- February 10, 2023
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph (PM) with new safety information about Steven Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AZOPT | Not yet assigned | — |
Medicinal ingredients
- BRINZOLAMIDE 1 PER